Data Availability
In this retrospective study of adult inpatients in three hospitals in China, we identified anti-MDA5 Ab in 48.2% of patients with COVID-19. The anti-MDA5 Ab positive patients tended to represent with severe disease (88.6% vs 66.9%, P<0.0001), and the titer of anti-MDA5 Ab was significantly elevated in the non-survivals (P=0.030) than that in the survivals. We also demonstrated that early profiling of anti-MDA5 Ab could distinguish severe patients from those with non-severe ones. Overall, our data suggest that early screening and serially monitoring of anti-MDA5 Ab might help identify severe COVID-19 patients with poor outcomes, or those who would probably benefit from anti-inflammation and immunosuppressive therapy. The findings are yet to be validated in a larger population of different ethnicities in future.
